Ignite Creation Date:
2024-05-05 @ 11:36 PM
Last Modification Date:
2024-10-26 @ 10:37 AM
Study NCT ID:
NCT01379534
Status:
COMPLETED
Last Update Posted:
2015-05-20
First Post:
2011-06-06
Brief Title:
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced andor Metastatic Endometrial Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| VEGF |
| Solid Tumors and Advanced Endometrial Cancer |
| Endometrial Cancer |
| Second-line Treatment |
Keywords:
| Name | View |
|---|---|
| Solid tumors | View |
| Endometrial Cancer | View |
| VEGF | View |
| Neoplasms | View |
| Uterine Neoplasms | View |
| Cancer | View |
| Uterine Diseases | View |
| Female Genital Diseases | View |
| Oral Administration | View |
| Tablets | View |
| CHIR258 | View |
| CHIR-258 | View |
| TKI258 | View |
| TKI-258 | View |
| TKI 258 | View |
| advanced endometrial cancer | View |
| Second-line treatment | View |
| Endometrial Neoplasms | View |
| Female Genital Neoplasms | View |
| Carcinoma | View |
| Tumors | View |
| Capsules | View |
| CHIR 258 | View |